Acute lysyl oxidase inhibition alters microvascular function in normotensive but not hypertensive men and women
The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human research is sparse, as long-term LOX inhibition in animals causes vascular instability. Our aim was to evaluate the effects of LOX inhibition o...
Saved in:
Published in | American journal of physiology. Heart and circulatory physiology Vol. 314; no. 3; pp. H424 - H433 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Physiological Society
01.03.2018
|
Series | Extracellular Matrix in Cardiovascular Pathophysiology |
Subjects | |
Online Access | Get full text |
ISSN | 0363-6135 1522-1539 1522-1539 |
DOI | 10.1152/ajpheart.00521.2017 |
Cover
Loading…
Abstract | The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human research is sparse, as long-term LOX inhibition in animals causes vascular instability. Our aim was to evaluate the effects of LOX inhibition on cutaneous microvascular function to determine whether LOX function was upregulated in hypertensive humans. Four intradermal microdialysis fibers were placed in the forearm of 10 young [age: 24 ± 1 yr, mean arterial pressure (MAP): 87 ± 2 mmHg], 10 normotensive (age: 50 ± 2 yr, MAP: 84 ± 1 mmHg), and 10 hypertensive (age: 53 ± 2 yr, MAP: 112 ± 2 mmHg) subjects. Two sites were perfused with 10 mM β-aminopropionitrile (BAPN) to inhibit LOX. The remaining two sites were perfused with lactated Ringer solution (control). A norepinephrine dose response (10
-10
M) was performed to examine receptor-mediated vasoconstrictor function. A sodium nitroprusside dose response (10
-10
M) was performed to examine vascular smooth muscle vasodilator function. Red blood cell flux was measured via laser-Doppler flowmetry and normalized to cutaneous vascular conductance (flux/MAP). LogEC
values were calculated to determine changes in vasosensitivity. Skin tissue samples were analyzed for both extracellular matrix-bound and soluble LOX. LOX inhibition augmented vasoconstrictor sensitivity in young (control: -6.0 and BAPN: -7.1, P = 0.03) and normotensive (control: -4.8 and BAPN: -7.0, P = 0.01) but not hypertensive (control: -6.0 and BAPN: -6.1, P = 0.79) men and women. Relative to young subjects, extracellular matrix-bound LOX expression was higher in hypertensive subjects (young: 100 ± 8 and hypertensive: 162 ± 8, P = 0.002). These results suggest that upregulated LOX may contribute to the vascular stiffness and microvascular dysfunction characteristic in hypertension. NEW & NOTEWORTHY Matrix-bound lysyl oxidase (LOX) and LOX-like 2 expression are upregulated in the microvasculature of hypertensive men and women. Microvascular responsiveness to exogenous stimuli is altered with localized LOX inhibition in healthy men and women but not hypertensive adults. The LOX family differentially affects microvascular function in hypertensive and normotensive men and women. |
---|---|
AbstractList | The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human research is sparse, as long-term LOX inhibition in animals causes vascular instability. Our aim was to evaluate the effects of LOX inhibition on cutaneous microvascular function to determine whether LOX function was upregulated in hypertensive humans. Four intradermal microdialysis fibers were placed in the forearm of 10 young [age: 24 ± 1 yr, mean arterial pressure (MAP): 87 ± 2 mmHg], 10 normotensive (age: 50 ± 2 yr, MAP: 84 ± 1 mmHg), and 10 hypertensive (age: 53 ± 2 yr, MAP: 112 ± 2 mmHg) subjects. Two sites were perfused with 10 mM β-aminopropionitrile (BAPN) to inhibit LOX. The remaining two sites were perfused with lactated Ringer solution (control). A norepinephrine dose response (10-12-10-2 M) was performed to examine receptor-mediated vasoconstrictor function. A sodium nitroprusside dose response (10-8-10-1.3M) was performed to examine vascular smooth muscle vasodilator function. Red blood cell flux was measured via laser-Doppler flowmetry and normalized to cutaneous vascular conductance (flux/MAP). LogEC50 values were calculated to determine changes in vasosensitivity. Skin tissue samples were analyzed for both extracellular matrix-bound and soluble LOX. LOX inhibition augmented vasoconstrictor sensitivity in young (control: -6.0 and BAPN: -7.1, P = 0.03) and normotensive (control: -4.8 and BAPN: -7.0, P = 0.01) but not hypertensive (control: -6.0 and BAPN: -6.1, P = 0.79) men and women. Relative to young subjects, extracellular matrix-bound LOX expression was higher in hypertensive subjects (young: 100 ± 8 and hypertensive: 162 ± 8, P = 0.002). These results suggest that upregulated LOX may contribute to the vascular stiffness and microvascular dysfunction characteristic in hypertension. The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human research is sparse, as long-term LOX inhibition in animals causes vascular instability. Our aim was to evaluate the effects of LOX inhibition on cutaneous microvascular function to determine whether LOX function was upregulated in hypertensive humans. Four intradermal microdialysis fibers were placed in the forearm of 10 young [age: 24 ± 1 yr, mean arterial pressure (MAP): 87 ± 2 mmHg], 10 normotensive (age: 50 ± 2 yr, MAP: 84 ± 1 mmHg), and 10 hypertensive (age: 53 ± 2 yr, MAP: 112 ± 2 mmHg) subjects. Two sites were perfused with 10 mM β-aminopropionitrile (BAPN) to inhibit LOX. The remaining two sites were perfused with lactated Ringer solution (control). A norepinephrine dose response (10 −12 −10 −2 M) was performed to examine receptor-mediated vasoconstrictor function. A sodium nitroprusside dose response (10 −8 −10 −1.3 M) was performed to examine vascular smooth muscle vasodilator function. Red blood cell flux was measured via laser-Doppler flowmetry and normalized to cutaneous vascular conductance (flux/MAP). LogEC 50 values were calculated to determine changes in vasosensitivity. Skin tissue samples were analyzed for both extracellular matrix-bound and soluble LOX. LOX inhibition augmented vasoconstrictor sensitivity in young (control: −6.0 and BAPN: −7.1, P = 0.03) and normotensive (control: −4.8 and BAPN: −7.0, P = 0.01) but not hypertensive (control: −6.0 and BAPN: −6.1, P = 0.79) men and women. Relative to young subjects, extracellular matrix-bound LOX expression was higher in hypertensive subjects (young: 100 ± 8 and hypertensive: 162 ± 8, P = 0.002). These results suggest that upregulated LOX may contribute to the vascular stiffness and microvascular dysfunction characteristic in hypertension. NEW & NOTEWORTHY Matrix-bound lysyl oxidase (LOX) and LOX-like 2 expression are upregulated in the microvasculature of hypertensive men and women. Microvascular responsiveness to exogenous stimuli is altered with localized LOX inhibition in healthy men and women but not hypertensive adults. The LOX family differentially affects microvascular function in hypertensive and normotensive men and women. The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human research is sparse, as long-term LOX inhibition in animals causes vascular instability. Our aim was to evaluate the effects of LOX inhibition on cutaneous microvascular function to determine whether LOX function was upregulated in hypertensive humans. Four intradermal microdialysis fibers were placed in the forearm of 10 young [age: 24 ± 1 yr, mean arterial pressure (MAP): 87 ± 2 mmHg], 10 normotensive (age: 50 ± 2 yr, MAP: 84 ± 1 mmHg), and 10 hypertensive (age: 53 ± 2 yr, MAP: 112 ± 2 mmHg) subjects. Two sites were perfused with 10 mM β-aminopropionitrile (BAPN) to inhibit LOX. The remaining two sites were perfused with lactated Ringer solution (control). A norepinephrine dose response (10 -10 M) was performed to examine receptor-mediated vasoconstrictor function. A sodium nitroprusside dose response (10 -10 M) was performed to examine vascular smooth muscle vasodilator function. Red blood cell flux was measured via laser-Doppler flowmetry and normalized to cutaneous vascular conductance (flux/MAP). LogEC values were calculated to determine changes in vasosensitivity. Skin tissue samples were analyzed for both extracellular matrix-bound and soluble LOX. LOX inhibition augmented vasoconstrictor sensitivity in young (control: -6.0 and BAPN: -7.1, P = 0.03) and normotensive (control: -4.8 and BAPN: -7.0, P = 0.01) but not hypertensive (control: -6.0 and BAPN: -6.1, P = 0.79) men and women. Relative to young subjects, extracellular matrix-bound LOX expression was higher in hypertensive subjects (young: 100 ± 8 and hypertensive: 162 ± 8, P = 0.002). These results suggest that upregulated LOX may contribute to the vascular stiffness and microvascular dysfunction characteristic in hypertension. NEW & NOTEWORTHY Matrix-bound lysyl oxidase (LOX) and LOX-like 2 expression are upregulated in the microvasculature of hypertensive men and women. Microvascular responsiveness to exogenous stimuli is altered with localized LOX inhibition in healthy men and women but not hypertensive adults. The LOX family differentially affects microvascular function in hypertensive and normotensive men and women. The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human research is sparse, as long-term LOX inhibition in animals causes vascular instability. Our aim was to evaluate the effects of LOX inhibition on cutaneous microvascular function to determine whether LOX function was upregulated in hypertensive humans. Four intradermal microdialysis fibers were placed in the forearm of 10 young [age: 24 ± 1 yr, mean arterial pressure (MAP): 87 ± 2 mmHg], 10 normotensive (age: 50 ± 2 yr, MAP: 84 ± 1 mmHg), and 10 hypertensive (age: 53 ± 2 yr, MAP: 112 ± 2 mmHg) subjects. Two sites were perfused with 10 mM β-aminopropionitrile (BAPN) to inhibit LOX. The remaining two sites were perfused with lactated Ringer solution (control). A norepinephrine dose response (10-12-10-2 M) was performed to examine receptor-mediated vasoconstrictor function. A sodium nitroprusside dose response (10-8-10-1.3 M) was performed to examine vascular smooth muscle vasodilator function. Red blood cell flux was measured via laser-Doppler flowmetry and normalized to cutaneous vascular conductance (flux/MAP). LogEC50 values were calculated to determine changes in vasosensitivity. Skin tissue samples were analyzed for both extracellular matrix-bound and soluble LOX. LOX inhibition augmented vasoconstrictor sensitivity in young (control: -6.0 and BAPN: -7.1, P = 0.03) and normotensive (control: -4.8 and BAPN: -7.0, P = 0.01) but not hypertensive (control: -6.0 and BAPN: -6.1, P = 0.79) men and women. Relative to young subjects, extracellular matrix-bound LOX expression was higher in hypertensive subjects (young: 100 ± 8 and hypertensive: 162 ± 8, P = 0.002). These results suggest that upregulated LOX may contribute to the vascular stiffness and microvascular dysfunction characteristic in hypertension. NEW & NOTEWORTHY Matrix-bound lysyl oxidase (LOX) and LOX-like 2 expression are upregulated in the microvasculature of hypertensive men and women. Microvascular responsiveness to exogenous stimuli is altered with localized LOX inhibition in healthy men and women but not hypertensive adults. The LOX family differentially affects microvascular function in hypertensive and normotensive men and women.The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human research is sparse, as long-term LOX inhibition in animals causes vascular instability. Our aim was to evaluate the effects of LOX inhibition on cutaneous microvascular function to determine whether LOX function was upregulated in hypertensive humans. Four intradermal microdialysis fibers were placed in the forearm of 10 young [age: 24 ± 1 yr, mean arterial pressure (MAP): 87 ± 2 mmHg], 10 normotensive (age: 50 ± 2 yr, MAP: 84 ± 1 mmHg), and 10 hypertensive (age: 53 ± 2 yr, MAP: 112 ± 2 mmHg) subjects. Two sites were perfused with 10 mM β-aminopropionitrile (BAPN) to inhibit LOX. The remaining two sites were perfused with lactated Ringer solution (control). A norepinephrine dose response (10-12-10-2 M) was performed to examine receptor-mediated vasoconstrictor function. A sodium nitroprusside dose response (10-8-10-1.3 M) was performed to examine vascular smooth muscle vasodilator function. Red blood cell flux was measured via laser-Doppler flowmetry and normalized to cutaneous vascular conductance (flux/MAP). LogEC50 values were calculated to determine changes in vasosensitivity. Skin tissue samples were analyzed for both extracellular matrix-bound and soluble LOX. LOX inhibition augmented vasoconstrictor sensitivity in young (control: -6.0 and BAPN: -7.1, P = 0.03) and normotensive (control: -4.8 and BAPN: -7.0, P = 0.01) but not hypertensive (control: -6.0 and BAPN: -6.1, P = 0.79) men and women. Relative to young subjects, extracellular matrix-bound LOX expression was higher in hypertensive subjects (young: 100 ± 8 and hypertensive: 162 ± 8, P = 0.002). These results suggest that upregulated LOX may contribute to the vascular stiffness and microvascular dysfunction characteristic in hypertension. NEW & NOTEWORTHY Matrix-bound lysyl oxidase (LOX) and LOX-like 2 expression are upregulated in the microvasculature of hypertensive men and women. Microvascular responsiveness to exogenous stimuli is altered with localized LOX inhibition in healthy men and women but not hypertensive adults. The LOX family differentially affects microvascular function in hypertensive and normotensive men and women. |
Author | Santhanam, Lakshmi Craighead, Daniel H. Wang, Huilei Alexander, Lacy M. |
Author_xml | – sequence: 1 givenname: Daniel H. surname: Craighead fullname: Craighead, Daniel H. organization: The Pennsylvania State University, University Park, Pennsylvania – sequence: 2 givenname: Huilei surname: Wang fullname: Wang, Huilei organization: Johns Hopkins University School of Medicine, Baltimore, Maryland – sequence: 3 givenname: Lakshmi surname: Santhanam fullname: Santhanam, Lakshmi organization: Johns Hopkins University School of Medicine, Baltimore, Maryland – sequence: 4 givenname: Lacy M. surname: Alexander fullname: Alexander, Lacy M. organization: The Pennsylvania State University, University Park, Pennsylvania |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29167120$$D View this record in MEDLINE/PubMed |
BookMark | eNp9UV1rFDEUDVKx2-ovECTgS19mzcckk7wIpVgVCr7oc8hk7rhZZpI1yazuvzfbdkX74FPCPR-ce88FOgsxAEKvKVlTKtg7u91twKayJkQwumaEds_QqiKsoYLrM7QiXPJGUi7O0UXOW1KJneQv0DnTVHaUkRWK124pgKdDPkw4_vKDzYB92PjeFx8DtlOBlPHsXYp7m90y2YTHJbh71AccYppjgZD9HnC_lDooeHPYQToNZ6g2YcA_Y_29RM9HO2V49fheom-3H77efGruvnz8fHN917iW89LoVmquleiUHYduVL1TvaaUjlbRgWvBgOtBWKGpGIhSvWyh1ZY6omQnmQN-id4_-O6WfobBQSjJTmaX_GzTwUTrzb9I8BvzPe6NUFozyavB1aNBij8WyMXMPjuYJhsgLtlQLTslCRekUt8-oW7jkkJdzzDCKNNE6Lay3vyd6E-UUxeVoB8I9dQ5JxiN88Ue71wD-slQYo69m1Pv5r53c-y9avkT7cn-f6rf2Ne2JQ |
CitedBy_id | crossref_primary_10_1016_j_bbadis_2019_165645 crossref_primary_10_1038_s44161_023_00311_0 crossref_primary_10_1152_ajpcell_00176_2023 crossref_primary_10_1152_ajpheart_00602_2021 crossref_primary_10_1152_ajpheart_00729_2017 crossref_primary_10_1152_ajpheart_00179_2020 crossref_primary_10_1002_adtp_201900119 crossref_primary_10_3390_ijms21165913 crossref_primary_10_1152_ajpheart_00177_2020 crossref_primary_10_1155_2022_5299370 crossref_primary_10_1152_ajpheart_00404_2021 crossref_primary_10_3389_fphys_2021_746278 crossref_primary_10_1152_ajpheart_00631_2018 |
Cites_doi | 10.1161/01.ATV.0000160548.78317.29 10.1016/j.atherosclerosis.2003.11.015 10.1074/jbc.M210144200 10.1111/j.0022-202X.2004.22330.x 10.1152/japplphysiol.00575.2014 10.1177/1708538113478741 10.1016/j.jvs.2005.05.019 10.1113/jphysiol.2007.128959 10.3892/mmr.2016.5474 10.1136/hrt.2004.053074 10.1007/BF02505035 10.1161/HYPERTENSIONAHA.107.089391 10.1016/j.mvr.2013.02.005 10.1042/CS20120619 10.1093/ajh/hpx127 10.1097/HJH.0b013e328364ca4c 10.1177/000331976801900705 10.1152/japplphysiol.00498.2017 10.1113/JP270062 10.1161/CIR.0000000000000485 10.1097/00004872-198702000-00013 10.1161/HYP.0000000000000018 10.1152/ajpheart.00232.2013 10.1152/japplphysiol.01354.2011 10.1371/journal.pone.0124013 10.1021/acs.jmedchem.7b00345 10.1158/0008-5472.CAN-04-1543 10.1161/01.CIR.0000038109.84500.1E 10.1161/HYPERTENSIONAHA.108.125278 10.1002/jcb.10413 10.1158/0008-5472.CAN-06-3197 10.15252/embj.201489975 10.1016/S0014-2999(02)02825-X 10.1152/japplphysiol.00858.2007 10.1016/j.tips.2006.07.008 10.1158/0008-5472.CAN-05-1274 10.1002/1097-4644(20000915)78:4<550::AID-JCB4>3.0.CO;2-8 10.1161/01.CIR.64.4.760 10.1161/01.ATV.0000033818.21748.99 10.1152/ajpheart.00262.2004 10.1161/ATVBAHA.114.303534 10.1016/j.cellsig.2015.07.001 10.1093/cvr/cvn102 10.1016/0304-4165(92)90095-C 10.1161/HYPERTENSIONAHA.111.178129 10.1161/CIRCRESAHA.116.303596 10.1016/0022-4804(79)90134-3 10.1161/01.HYP.14.2.177 10.1158/0008-5472.CAN-12-2447 10.1152/ajpregu.00269.2014 10.1016/j.ajpath.2014.11.009 10.1111/micc.12382 10.1161/01.HYP.13.6.870 10.1152/japplphysiol.01257.2011 10.1161/01.HYP.0000107251.49515.c2 10.1161/01.HYP.34.4.724 10.1152/japplphysiol.00918.2015 |
ContentType | Journal Article |
Copyright | Copyright American Physiological Society Mar 2018 Copyright © 2018 the American Physiological Society 2018 American Physiological Society |
Copyright_xml | – notice: Copyright American Physiological Society Mar 2018 – notice: Copyright © 2018 the American Physiological Society 2018 American Physiological Society |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7QR 7TS 7U7 8FD C1K FR3 P64 7X8 5PM |
DOI | 10.1152/ajpheart.00521.2017 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Physical Education Index Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Technology Research Database Toxicology Abstracts Chemoreception Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Physical Education Index Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Technology Research Database MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
DocumentTitleAlternate | LOX INHIBITION AND MICROVASCULAR FUNCTION |
EISSN | 1522-1539 |
EndPage | H433 |
ExternalDocumentID | PMC5899263 29167120 10_1152_ajpheart_00521_2017 |
Genre | Comparative Study Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: T32 DK007135 – fundername: NHLBI NIH HHS grantid: R01 HL093238 – fundername: ; ; grantid: R01 HL093238-07 – fundername: ; grantid: Predoctoral Research Grant |
GroupedDBID | --- 23M 2WC 39C 3O- 4.4 53G 5GY 5VS 6J9 8M5 AAFWJ AAYXX ABJNI ACBEA ACIWK ACPRK ADBBV AENEX AFFNX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BKKCC BKOMP BTFSW C1A CITATION E3Z EBS EJD EMOBN F5P GX1 H13 ITBOX KQ8 OK1 P2P PQQKQ RAP RHI RPL RPRKH TR2 UKR W8F WH7 WOQ XSW YSK YYP ~02 CGR CUY CVF ECM EIF NPM 7QP 7QR 7TS 7U7 8FD C1K FR3 P64 7X8 5PM |
ID | FETCH-LOGICAL-c433t-9469398578afd7f8bc8b9111fa81d3952e39d5a5915d088b64e49a1c086762ce3 |
ISSN | 0363-6135 1522-1539 |
IngestDate | Thu Aug 21 14:14:31 EDT 2025 Thu Jul 10 21:29:25 EDT 2025 Mon Jun 30 16:49:00 EDT 2025 Mon Jul 21 06:05:50 EDT 2025 Tue Jul 01 01:16:35 EDT 2025 Thu Apr 24 23:02:28 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | lysyl oxidase microvascular hypertension |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c433t-9469398578afd7f8bc8b9111fa81d3952e39d5a5915d088b64e49a1c086762ce3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://www.physiology.org/doi/pdf/10.1152/ajpheart.00521.2017 |
PMID | 29167120 |
PQID | 2021290594 |
PQPubID | 48261 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5899263 proquest_miscellaneous_1967860350 proquest_journals_2021290594 pubmed_primary_29167120 crossref_citationtrail_10_1152_ajpheart_00521_2017 crossref_primary_10_1152_ajpheart_00521_2017 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-03-01 |
PublicationDateYYYYMMDD | 2018-03-01 |
PublicationDate_xml | – month: 03 year: 2018 text: 2018-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Bethesda – name: Bethesda, MD |
PublicationSeriesTitle | Extracellular Matrix in Cardiovascular Pathophysiology |
PublicationTitle | American journal of physiology. Heart and circulatory physiology |
PublicationTitleAlternate | Am J Physiol Heart Circ Physiol |
PublicationYear | 2018 |
Publisher | American Physiological Society |
Publisher_xml | – name: American Physiological Society |
References | B20 B21 B22 B23 B24 B25 Rush JW (B47) 2007; 37 B26 B27 B28 B29 B30 B31 B32 B33 B34 B35 B37 B38 B39 B1 B2 B3 B4 B5 B6 B7 B8 Gillespie CD (B18) 2013; 62 B40 B41 B42 B43 B44 B45 B46 B48 B49 Nakashima Y (B36) 1992; 140 Cox RH (B9) 1988; 25 B50 B51 B52 B53 B10 B54 B11 B55 B12 B56 B13 B57 B14 B15 B59 B16 B17 B19 B60 B61 B62 29351472 - Am J Physiol Heart Circ Physiol. 2018 Apr 1;314(4):H784-H786 |
References_xml | – ident: B62 doi: 10.1161/01.ATV.0000160548.78317.29 – ident: B15 doi: 10.1016/j.atherosclerosis.2003.11.015 – ident: B24 doi: 10.1074/jbc.M210144200 – ident: B38 doi: 10.1111/j.0022-202X.2004.22330.x – volume: 62 start-page: 144 year: 2013 ident: B18 publication-title: MMWR Suppl – ident: B21 doi: 10.1152/japplphysiol.00575.2014 – ident: B28 doi: 10.1177/1708538113478741 – ident: B1 doi: 10.1016/j.jvs.2005.05.019 – ident: B22 doi: 10.1113/jphysiol.2007.128959 – ident: B60 doi: 10.3892/mmr.2016.5474 – ident: B50 doi: 10.1136/hrt.2004.053074 – ident: B17 doi: 10.1007/BF02505035 – ident: B59 doi: 10.1161/HYPERTENSIONAHA.107.089391 – ident: B53 doi: 10.1016/j.mvr.2013.02.005 – ident: B19 doi: 10.1042/CS20120619 – ident: B11 doi: 10.1093/ajh/hpx127 – ident: B33 doi: 10.1097/HJH.0b013e328364ca4c – ident: B51 doi: 10.1177/000331976801900705 – ident: B52 doi: 10.1152/japplphysiol.00498.2017 – ident: B20 doi: 10.1113/JP270062 – ident: B5 doi: 10.1161/CIR.0000000000000485 – ident: B39 doi: 10.1097/00004872-198702000-00013 – ident: B43 doi: 10.1161/HYP.0000000000000018 – volume: 140 start-page: 959 year: 1992 ident: B36 publication-title: Am J Pathol – ident: B49 doi: 10.1152/ajpheart.00232.2013 – ident: B6 doi: 10.1152/japplphysiol.01354.2011 – ident: B13 doi: 10.1371/journal.pone.0124013 – ident: B45 doi: 10.1021/acs.jmedchem.7b00345 – ident: B26 doi: 10.1158/0008-5472.CAN-04-1543 – ident: B31 doi: 10.1161/01.CIR.0000038109.84500.1E – ident: B30 doi: 10.1161/HYPERTENSIONAHA.108.125278 – ident: B25 doi: 10.1002/jcb.10413 – ident: B14 doi: 10.1158/0008-5472.CAN-06-3197 – ident: B34 doi: 10.15252/embj.201489975 – volume: 25 start-page: 53 year: 1988 ident: B9 publication-title: Blood Vessels – ident: B16 doi: 10.1016/S0014-2999(02)02825-X – ident: B23 doi: 10.1152/japplphysiol.00858.2007 – ident: B10 doi: 10.1016/j.tips.2006.07.008 – ident: B40 doi: 10.1158/0008-5472.CAN-05-1274 – ident: B29 doi: 10.1002/1097-4644(20000915)78:4<550::AID-JCB4>3.0.CO;2-8 – ident: B35 doi: 10.1161/01.CIR.64.4.760 – ident: B42 doi: 10.1161/01.ATV.0000033818.21748.99 – ident: B48 doi: 10.1152/ajpheart.00262.2004 – ident: B37 doi: 10.1161/ATVBAHA.114.303534 – ident: B55 doi: 10.1016/j.cellsig.2015.07.001 – volume: 37 start-page: 185 year: 2007 ident: B47 publication-title: Clin Hemorheol Microcirc – ident: B41 doi: 10.1093/cvr/cvn102 – ident: B46 doi: 10.1016/0304-4165(92)90095-C – ident: B54 doi: 10.1161/HYPERTENSIONAHA.111.178129 – ident: B27 doi: 10.1161/CIRCRESAHA.116.303596 – ident: B3 doi: 10.1016/0022-4804(79)90134-3 – ident: B2 doi: 10.1161/01.HYP.14.2.177 – ident: B4 doi: 10.1158/0008-5472.CAN-12-2447 – ident: B57 doi: 10.1152/ajpregu.00269.2014 – ident: B44 doi: 10.1016/j.ajpath.2014.11.009 – ident: B12 doi: 10.1111/micc.12382 – ident: B61 doi: 10.1161/01.HYP.13.6.870 – ident: B56 doi: 10.1152/japplphysiol.01257.2011 – ident: B8 doi: 10.1161/01.HYP.0000107251.49515.c2 – ident: B32 doi: 10.1161/01.HYP.34.4.724 – ident: B7 doi: 10.1152/japplphysiol.00918.2015 – reference: 29351472 - Am J Physiol Heart Circ Physiol. 2018 Apr 1;314(4):H784-H786 |
SSID | ssj0005763 |
Score | 2.3195615 |
Snippet | The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | H424 |
SubjectTerms | Adult Age Amino Acid Oxidoreductases - antagonists & inhibitors Amino Acid Oxidoreductases - metabolism Aminopropionitrile - administration & dosage Blood Pressure Collagen Conductance Cross-linking Crosslinking Doppler effect Enzyme Inhibitors - administration & dosage Erythrocytes Extracellular matrix Female Fibers Forearm Humans Hypertension Hypertension - diagnosis Hypertension - physiopathology Inhibition Liquid oxygen Lysyl oxidase Male Matrix Men Microcirculation - drug effects Microdialysis Microvasculature Microvessels - drug effects Microvessels - enzymology Microvessels - physiopathology Middle Aged Muscles Norepinephrine Oxidase Protein-Lysine 6-Oxidase - antagonists & inhibitors Protein-Lysine 6-Oxidase - metabolism Skin Skin - blood supply Smooth muscle Sodium Sodium nitroprusside Stability Stability analysis Stiffness Vasoconstriction - drug effects Vasodilation - drug effects Women Young Adult |
Title | Acute lysyl oxidase inhibition alters microvascular function in normotensive but not hypertensive men and women |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29167120 https://www.proquest.com/docview/2021290594 https://www.proquest.com/docview/1967860350 https://pubmed.ncbi.nlm.nih.gov/PMC5899263 |
Volume | 314 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAvCDYuhYGMhHgpCW0Sp_FjhUARMATSJu0tShxHzVjTqU0lyn_lv_DZTpx0mybGS1TZrtP0fDn3c0zIm8IvwoyF0hF5WDhBOJFOFgnpyECMRRhlPNVnAx59C-OT4PMpOx0M_vSyljZ15orf19aV_A9VMQa6qirZW1DWbooBfAZ9cQWFcf0nGs-EivKfb9dbaJS_yhwSaVRW8zIrzfnfKhK-Hi1Uzp3NOFWCrE1wrKCwLm0K-6bGQD2awzJdtYMLaZKVdaOGviJrIz291hPaS6Ld9K4qb1qZ5HVRrtSddTC_W2FjH6tUZZqkeVfvPordzs1vWFG8AfMqrTcIaJinlYHy1_Tner6wc7Zgx8yJ7ejI7Xs2JlGX2mUrunyYtqadiSsbBg3jGVya9zm4b-pQG6j6PX4cB6ZCu5HtcWC6blyVG0z1oU3PLtQx4rWrnOXKeWDKSne7dF-SnjanUVtTzEvaTRK9SaI2uUPuerBilNz48qNrZg9Tz29D6eoxm6ZY2OT9Nb9kV3G6Yg1dTurtaUnHD8mDxryhM4PVR2Qgq31yMKtA_sWWvqXfLQD2yb2jJq_jgCw1kqlGMm2QTDskU4NkuoNk2iIZC2kfyRRIxkBN-0imwC8FMKhG8mNy8unj8YfYaY4CcQRIVjs8CLnPI4iXtMinRZQJsBGI6SKFveVz5kmf5yxlfMJyyM0sDGQANiNgsEPaC-k_IXvVspLPCOUiSid5NvbEuIB6GmU5TGwRBUwdnSCLfEi89n9ORNMnXx3Xcp7cQOEheWe_dGHaxNy8_LAlYNK8pmtMeMopzHgwJK_tNLi9CuGllVxu1gnk5TQKVTbAkDw19Lb382DpTSceZqY7SLALVCf53ZmqnOuO8izi3Av957d7ihfkfvfaHpK9erWRL6Gi19krDfS_Mcvw6Q |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acute+lysyl+oxidase+inhibition+alters+microvascular+function+in+normotensive+but+not+hypertensive+men+and+women&rft.jtitle=American+journal+of+physiology.+Heart+and+circulatory+physiology&rft.au=Craighead%2C+Daniel+H.&rft.au=Wang%2C+Huilei&rft.au=Santhanam%2C+Lakshmi&rft.au=Alexander%2C+Lacy+M.&rft.date=2018-03-01&rft.issn=0363-6135&rft.eissn=1522-1539&rft.volume=314&rft.issue=3&rft.spage=H424&rft.epage=H433&rft_id=info:doi/10.1152%2Fajpheart.00521.2017&rft.externalDBID=n%2Fa&rft.externalDocID=10_1152_ajpheart_00521_2017 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0363-6135&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0363-6135&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0363-6135&client=summon |